drugset / Trial / NCT02154529
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
Timeline
- Start
- 2014-05
- Primary completion
- 2015-09-13
- Completion
- 2015-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesevatinib | Small molecule | 150 mg | Oral |
| Subject | Tesevatinib | Small molecule | 250 mg | Oral |
| Subject | Tesevatinib | Small molecule | 300 mg | Oral |
| Subject | Tesevatinib | Small molecule | 350 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |